Payment overview · 2025
General Payments
$916.38
41 reported records · 15 companies
Healthcare provider profile · identity verified
Rada Norov, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1326435512
Verified facts
What the public records show
CMS Open Payments records show Rada Norov, M.D. received $916.38 in general payments during 2025 across 41 reported records.
Axsome Therapeutics, Inc. accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $266.50 | 29.1% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $152.55 | 16.6% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.41 | 10.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.07 | 8.0% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.63 | 4.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.80 | 4.2% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $34.02 | 3.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.41 | 3.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $32.30 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.69 | 3.0% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.44 | 3.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $26.06 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.19 | 2.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.77 | 2.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $19.54 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $916.38 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $266.50 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $126.68 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $114.16 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.07 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.49 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.63 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.80 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $34.02 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.41 | 1 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $32.30 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $27.44 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 38 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 117 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
81 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
117 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 274 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 191 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 49 |
| Losartan Potassium | Losartan Potassium | 162 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 131 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 117 | 24 |
| Eliquis | Apixaban | 116 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 33 |
| Famotidine | Famotidine | 107 | 28 |
| Omeprazole | Omeprazole | 107 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 29 |
| Gabapentin | Gabapentin | 104 | 32 |
| Doxepin Hcl | Doxepin Hcl | 101 | 13 |
| Furosemide | Furosemide | 99 | 23 |
| Lisinopril | Lisinopril | 99 | 25 |
| Metformin Hcl | Metformin Hcl | 98 | 29 |
| Diclofenac Sodium Er | Diclofenac Sodium | 96 | 18 |
| Mounjaro | Tirzepatide | 93 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 88 | 22 |
| Linzess | Linaclotide | 81 | 13 |
| Simvastatin | Simvastatin | 73 | 24 |
| Metformin Hcl Er | Metformin Hcl | 67 | 17 |
| Carvedilol | Carvedilol | 64 | 19 |
| Alprazolam | Alprazolam | 63 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 16 |
| Naproxen Sodium | Naproxen Sodium | 62 | 13 |
| Enalapril Maleate | Enalapril Maleate | 61 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 13 |
| Synthroid | Levothyroxine Sodium | 60 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 18 |
| Creon | Lipase/Protease/Amylase | 58 | suppressed |
| Meloxicam | Meloxicam | 58 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 23 |
| Prednisone | Prednisone | 55 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 19 |
| Allopurinol | Allopurinol | 52 | 16 |
| Repatha Sureclick | Evolocumab | 50 | 13 |
| Vascepa | Icosapent Ethyl | 50 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 13 |
| Zenpep | Lipase/Protease/Amylase | 49 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 47 | 22 |
| Azithromycin | Azithromycin | 46 | 39 |
| Sertraline Hcl | Sertraline Hcl | 46 | 19 |
| Celecoxib | Celecoxib | 45 | 23 |
| Montelukast Sodium | Montelukast Sodium | 44 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 16 |
| Dexilant | Dexlansoprazole | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 14 |
| Methylprednisolone | Methylprednisolone | 40 | 22 |
| Ozempic | Semaglutide | 40 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Folic Acid | Folic Acid | 39 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 39 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Gemtesa | Vibegron | 38 | 11 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 16 |
| Azelastine Hcl | Azelastine Hcl | 33 | 12 |
| Pregabalin | Pregabalin | 32 | 12 |
| Jardiance | Empagliflozin | 31 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 15 |
| Finasteride | Finasteride | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 14 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 19 |
| Atenolol | Atenolol | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Lovaza | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Aciphex | Rabeprazole Sodium | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Bystolic | Nebivolol Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 13 | suppressed |
| Singulair | Montelukast Sodium | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Restasis Multidose | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $916.38 · 41 records | Axsome Therapeutics, Inc. | Auvelity, ECC Solutions, FARXIGA, GEMTESA, NURTEC ODT, Ohtuvayre, Ozempic, PYRUKYND, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VERQUVO, ZAVZPRET, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error